biotech
biotech Articles
Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.
Published:
Last Updated:
Celgene is shuffling the deck in terms of its executive leadership, and one of its top executives is stepping down.
Published:
Last Updated:
Alkermes saw its shares drop early on Monday after the company announced that it received a Refusal to File letter from the FDA.
Published:
Last Updated:
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
Published:
Last Updated:
Shares of Shire saw a solid gain on Wednesday after the firm announced that it received an offer to be acquired by Takeda Pharmaceutical.
Published:
Last Updated:
Edge Therapeutics saw its shares plunge massively following the results from a late-stage trial.
Published:
Last Updated:
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
According to a recent analyst report by Janney, the National Institute of Health budget that was approved last Friday could be a big boost for some select biopharma stocks.
Published:
Last Updated:
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.
Published:
Last Updated:
While there is no guarantee that these four biotech companies are acquired, they are outstanding stocks to own in aggressive growth portfolios on their own.
Published:
Last Updated:
Progenics Pharmaceuticals shares took a big step back on Friday after the firm announced that it received an update from the FDA.
Published:
Cidara Therapeutics shares took a big step back on Monday, despite the firm reporting positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate.
Published:
Last Updated:
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Published:
Last Updated:
These three top companies have solid catalyst potential and already have shown good clinical results on their leading assets.
Published:
Last Updated:
Alexion Pharmaceuticals watched its shares make a solid gain on Thursday after the firm announced positive results from its late-stage trial of ALXN1210.
Published:
Last Updated: